Oracle R&D increased by 1.8% to $2.61B in Q4 2025 compared to the prior quarter. Year-over-year, this metric grew by 7.3%, from $2.43B to $2.61B. Over 4 years (FY 2021 to FY 2025), R&D shows an upward trend with a 10.9% CAGR.
Higher spending signals a commitment to innovation and future product launches, whereas significant cuts may indicate a shift toward short-term profitability.
Research and development expenses represent the costs incurred to discover new products, improve existing technologies,...
Highly comparable across pharmaceutical and medical device peers, where R&D intensity is a key metric for long-term valuation.
research_and_development| Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | Q2 '26 | Q3 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $1.72B | $1.68B | $1.75B | $1.82B | $1.97B | $2.09B | $2.16B | $2.15B | $2.23B | $2.22B | $2.23B | $2.25B | $2.23B | $2.31B | $2.47B | $2.43B | $2.65B | $2.49B | $2.56B | $2.61B |
| QoQ Change | — | -1.8% | +4.2% | +3.5% | +8.2% | +6.5% | +3.1% | -0.6% | +3.7% | -0.4% | +0.5% | +1.0% | -1.0% | +3.6% | +7.2% | -1.7% | +9.3% | -6.1% | +2.8% | +1.8% |
| YoY Change | — | — | — | — | +14.6% | +24.3% | +23.0% | +18.2% | +13.3% | +5.9% | +3.2% | +4.8% | +0.0% | +4.1% | +11.0% | +8.1% | +19.2% | +8.0% | +3.6% | +7.3% |